Technical Analysis for TENX - Tenax Therapeutics, Inc.
|Grade||Last Price||% Change||Price Change|
TENX closed down 3.55 percent on Friday, November 16, 2018, on 57 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
|Weak or Absent||Down||Down||Down|
|See historical TENX trend table...|
|Date||Alert Name||Type||% Chg|
|Nov 16||180 Bearish Setup||Bearish Swing Setup||0.00%|
|Nov 16||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||0.00%|
|Nov 16||Outside Day||Range Expansion||0.00%|
|Nov 16||Wide Bands||Range Expansion||0.00%|
|Nov 16||Oversold Stochastic||Weakness||0.00%|
|Nov 15||Stochastic Buy Signal||Bullish||-3.55%|
|Nov 15||Calm After Storm||Range Contraction||-3.55%|
|Nov 15||Narrow Range Bar||Range Contraction||-3.55%|
|Nov 15||NR7||Range Contraction||-3.55%|
|Nov 15||Lower Bollinger Band Walk||Weakness||-3.55%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the development and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company also develops Oxycyte, a systemic perfluorocarbon product for use as oxygen carrier in the situations of acute ischemia; and a range of perfluorocarbon-based oxygen carriers for use in personal care, topical wound healing, and other topical indications. Its Oxycyte is under Phase II-b clinical trials for the treatment of traumatic brain injury. In addition, the company offers Dermacyte line of topical cosmetic products that promote the appearance of skin health and other cosmetic benefits; and Wundecyte, a wound-healing gel. It sells Dermacyte through distribution agreements, on-line retailers, and direct sales to physician and medical spa facilities. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more TENX news...
|52 Week High||12.63|
|52 Week Low||3.75|
|200-Day Moving Average||6.0129|
|50-Day Moving Average||4.9075|
|20-Day Moving Average||4.6018|
|10-Day Moving Average||4.259|
|Average True Range||0.3222|
|Chandelier Exit (Long, 3 ATRs )||5.4234|
|Chandelier Exit (Short, 3 ATRs )||4.7166|
|Upper Bollinger Band||5.6013|
|Lower Bollinger Band||3.6023|
|Percent B (%b)||0.1|
|MACD Signal Line||-0.2192|
|Market Cap||107.31 Million|
|Num Shares||28.2 Million|
|Price-to-Earnings (P/E) Ratio||-2.66|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||4.30|
|Resistance 3 (R3)||4.35||4.24||4.21|
|Resistance 2 (R2)||4.24||4.11||4.21||4.18|
|Resistance 1 (R1)||4.02||4.04||3.97||3.97||4.16|
|Support 1 (S1)||3.69||3.78||3.64||3.64||3.44|
|Support 2 (S2)||3.58||3.71||3.55||3.42|
|Support 3 (S3)||3.36||3.58||3.39|
|Support 4 (S4)||3.31|